TCRX – tscan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access [Yahoo! Finance]
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $10.00 price target on the stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its price target lowered by analysts at Barclays PLC from $14.00 to $3.00. They now have an "overweight" rating on the stock.
Form EFFECT TScan Therapeutics, Inc.
Form S-8 TScan Therapeutics, Inc.
Form S-3 TScan Therapeutics, Inc.
Form 10-K TScan Therapeutics, Inc. For: Dec 31
Form 8-K TScan Therapeutics, Inc. For: Mar 05
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.